Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study

Leukemia Research
Aaron D GoldbergMelhem Solh

Abstract

There is a significant need for improved therapeutics in older patients with acute leukemia. Camidanlumab tesirine is an antibody-drug conjugate against CD25, an antigen expressed in several malignancies, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). This open-label, dose-escalation and -expansion study (NCT02588092) assessed the safety, activity, pharmacokinetics (PK), and immunogenicity of camidanlumab tesirine in patients with relapsed/refractory ALL/AML. A total of 35 patients (34 AML and 1 ALL) were enrolled and received camidanlumab tesirine intravenously at 3-92 μg/kg once every three weeks (Q3W, n = 26) or 30 or 37.5 μg/kg every week (QW, n = 9). One dose-limiting toxicity of maculopapular rash occurred in the 30 μg/kg QW group; the maximum tolerated dose was not reached. No additional safety concerns or adverse events (AEs) of interest were identified. The most common (>10 % of patients) Grade ≥3 treatment-emergent AEs were febrile neutropenia (25.7 %), lymphopenia, neutropenia, thrombocytopenia or fatigue (all 14.3 %), pneumonia, increased gamma-glutamyltransferase, and hypophosphatemia (each 11.4 %). No signal for serious immune-related AEs such as Guillain-Barré syndrome/polyradiculo...Continue Reading

References

Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Oct 16, 2007·Immunology Letters·Matthew A BurchillMichael A Farrar
Mar 27, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Monique TerwijnGerrit Jan Schuurhuis
Aug 13, 2009·Cancer Chemotherapy and Pharmacology·Yelena Y JanjigianNaiyer A Rizvi
Jul 16, 2010·Journal of Oncology·Lagadinou D EleniSpyridonidis Alexandros
Feb 25, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Igor PuzanovMace L Rothenberg
Apr 5, 2011·Expert Opinion on Investigational Drugs·John A Hartley
Jan 31, 2012·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Roland Martin
Apr 12, 2012·Blood·Nicola GökbugetUNKNOWN German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia
Nov 3, 2012·British Journal of Haematology·Jan CernyRajneesh Nath
Jun 12, 2013·Frontiers in Bioscience (Landmark Edition)·Andrew J CowanRoland B Walter
May 2, 2015·Journal of Clinical Medicine·Nestor R RamosChristopher S Hourigan
May 31, 2017·British Journal of Haematology·Michael J Flynn, John A Hartley
Aug 2, 2017·Leukemia Research·Sabine BlumMichael Lübbert
Apr 15, 2018·Cancer Medicine·Jessica L Krok-SchoenAshley E Rosko
Oct 17, 2018·Patient Related Outcome Measures·Lindsey HathawayMichael Keng
Feb 15, 2019·Proceedings of the National Academy of Sciences of the United States of America·Masanori OndaIra Pastan
Feb 21, 2019·American Journal of Hematology·Noelle V Frey
Mar 25, 2019·Current Oncology Reports·Maximilian Stahl, Aaron D Goldberg

❮ Previous
Next ❯

Citations

Aug 29, 2020·Expert Opinion on Biological Therapy·Roland B Walter
Dec 9, 2020·Journal of Hematology & Oncology·Jing Xu, Ting Niu
Jan 2, 2021·Journal of Hematology & Oncology·Katarzyna IżykowskaGrzegorz K Przybylski
Nov 8, 2020·Annual Review of Medicine·Willem W OverwijkJonathan Zalevsky
Jan 26, 2021·Current Hematologic Malignancy Reports·Narendranath Epperla, Mehdi Hamadani
Dec 10, 2020·Experimental Hematology & Oncology·Le Li, Ying Wang
Feb 26, 2021·Current Hematologic Malignancy Reports·Sangeetha VenugopalFarhad Ravandi
Jun 24, 2021·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·A MoeinafsharN Rezaei
Jun 26, 2021·Pharmacology & Therapeutics·Yiming JinAndrew J Wiemer
Aug 28, 2021·Journal of Clinical Medicine·Jamie L Stokke, Deepa Bhojwani
Jan 18, 2022·Leukemia & Lymphoma·Karan Chohan, Stephen M Ansell

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.